circCEIP-encoding peptide vaccine

The circCEIP-encoding peptide vaccine (also known as the circFAM53B-encoded peptide vaccine) is an academic research-stage cancer immunotherapy vaccine. It is based on cryptic antigenic peptides noncanonically translated by a tumor-specific circular RNA called circCEIP (Circular RNA CEIP, also known as circFAM53B). Identified through mass spectrometry of HLA class I (HLA-I) peptidomes coupled with ribosome sequencing of human breast cancer samples, these cryptic peptides have strong binding affinity to both HLA class I and HLA class II molecules. The vaccine works by presenting these cryptic peptides via HLA molecules to prime naive CD4+ and CD8+ T cells in an antigen-specific manner, thereby eliciting robust anti-tumor immunity. In preclinical studies, administration of the vaccine in mouse models of breast cancer and melanoma dramatically enhanced the infiltration of tumor-antigen-specific cytotoxic T cells, leading to effective tumor control. The research was led by investigators at Sun Yat-sen University.

Other names

circCEIP-encoded peptide vaccinecircFAM53B-encoded peptide vaccinecircFAM-53B-encoded peptide vaccinecircFAM 53B-encoded peptide vaccinecircFAM53B-encoding peptide vaccinecircFAM-53B-encoding peptide vaccinecircFAM 53B-encoding peptide vaccine